GSA Capital Partners LLP Increases Stock Position in Larimar Therapeutics, Inc. (NASDAQ:LRMR)

GSA Capital Partners LLP grew its holdings in Larimar Therapeutics, Inc. (NASDAQ:LRMR) by 108.9% during the 3rd quarter, Holdings Channel reports. The firm owned 107,408 shares of the company’s stock after buying an additional 55,984 shares during the period. GSA Capital Partners LLP’s holdings in Larimar Therapeutics were worth $704,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Quarry LP grew its holdings in shares of Larimar Therapeutics by 966.7% during the second quarter. Quarry LP now owns 8,000 shares of the company’s stock worth $58,000 after buying an additional 7,250 shares in the last quarter. Thoroughbred Financial Services LLC purchased a new stake in Larimar Therapeutics in the 2nd quarter worth approximately $94,000. EntryPoint Capital LLC acquired a new position in Larimar Therapeutics in the 1st quarter valued at $106,000. SG Americas Securities LLC purchased a new position in shares of Larimar Therapeutics during the 3rd quarter worth $94,000. Finally, AQR Capital Management LLC acquired a new stake in shares of Larimar Therapeutics during the second quarter worth $113,000. 91.92% of the stock is owned by hedge funds and other institutional investors.

Larimar Therapeutics Stock Performance

Larimar Therapeutics stock opened at $6.69 on Monday. The firm has a market capitalization of $426.89 million, a PE ratio of -5.82 and a beta of 0.95. Larimar Therapeutics, Inc. has a one year low of $2.77 and a one year high of $13.68. The stock’s 50 day moving average price is $7.38 and its 200 day moving average price is $7.93.

Larimar Therapeutics (NASDAQ:LRMR) last posted its earnings results on Wednesday, October 30th. The company reported ($0.24) EPS for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.13. During the same quarter last year, the firm earned ($0.21) EPS. On average, analysts forecast that Larimar Therapeutics, Inc. will post -1.16 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on the company. Baird R W raised Larimar Therapeutics to a “strong-buy” rating in a research note on Wednesday, September 4th. Wedbush initiated coverage on shares of Larimar Therapeutics in a research note on Thursday, October 3rd. They set an “outperform” rating and a $22.00 price objective for the company. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 target price on shares of Larimar Therapeutics in a research report on Thursday, October 31st. Robert W. Baird began coverage on Larimar Therapeutics in a research report on Wednesday, September 4th. They set an “outperform” rating and a $16.00 price target for the company. Finally, Oppenheimer started coverage on Larimar Therapeutics in a research note on Wednesday, October 16th. They set an “outperform” rating and a $26.00 price target for the company. Nine investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $20.43.

Larimar Therapeutics Company Profile

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.